Neurocrine Biosciences (NBIX) Could Be 31% Undervalued Following VYKAT XR And Alzheimer’s Trial News

Neurocrine Biosciences (NBIX) has drawn fresh attention after experts published perspectives on hyperphagia in Prader Willi syndrome that highlight VYKAT XR, alongside the launch of a Phase 2 Alzheimer’s trial for NBI-1117567.

Against this backdrop, Neurocrine Biosciences has had a mixed run, with a 7-day share price return of 5.15% at a last close of US$142.70, but a 90-day share price decline of 18.81% and a 1-year total shareholder return that is slightly negative at 0.90%. Meanwhile, the 3-year and 5-year total shareholder returns of 34.53% and 35.38% keep the longer-term story intact and leave recent product news as a potential catalyst for sentiment rather than a clear shift in trend so far.

Scan Neurocrine Biosciences alongside other neuroscience and rare disease plays by reviewing a hand picked group of 21 high quality undiscovered gems that share strong fundamentals and differentiated pipelines.

Neurocrine Biosciences now trades well below both analyst targets and intrinsic value estimates. The real puzzle is where fair value sits inside that wide range.

Most Popular Narrative: 31% Undervalued

On the current numbers, the most followed narrative puts Neurocrine Biosciences’ fair value at $206.81 against a last close of $142.70. This frames today’s discount through the lens of INGREZZA, CRENESSITY, VYKAT XR and a maturing late stage pipeline.

Expansion of Neurocrine Biosciences’ commercial portfolio beyond INGREZZA through the launch of CRENESSITY and the acquisition of VYKAT XR, which together supplied about 25% of Q2 2026 revenue off a roughly US$1b quarterly base, broadens revenue sources and can improve margin resilience as the company spreads infrastructure and R&D spending across three first in class endocrinology and neuropsychiatry franchises.

See why 51 investors see Neurocrine Biosciences as 31% undervalued.

Result: Fair Value of $206.81 (UNDERVALUED)

Still, the story around Neurocrine Biosciences can change quickly if INGREZZA pricing pressure bites harder than expected or if VYKAT XR safety concerns deepen.

Find out about the key risks to this Neurocrine Biosciences narrative.

Next Steps

Sentiment in this Neurocrine Biosciences story is mixed, so move quickly to test the numbers, pressure test the risks, and weigh the upside yourself. To see which potential rewards have investors optimistic, review the 4 key rewards.

Looking for more Neurocrine Biosciences sized opportunities?

You do not need to stop with Neurocrine Biosciences. Use the Simply Wall Street screener to uncover fresh ideas before they move without you.

• Target resilient balance sheets by filtering companies with strong financial footing through the list of solid balance sheet and fundamentals (25 results).
• Hunt for mispriced quality by scanning the 27 high quality undervalued stocks that combine healthy fundamentals with appealing valuations.
• Prioritise defence in choppy markets by reviewing 30 resilient stocks with low risk scores that carry lower overall risk scores.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com